---
document_datetime: 2023-09-21 17:20:20
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/velosulin-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: velosulin-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.9098409
conversion_datetime: 2025-12-31 03:40:34.99878
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MAJOR CHANGES 1

<!-- image -->

| No      | Scope                                                                                                                                                                                                                                                                                                                                                            | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0006  | Renewal of the Marketing Authorisation.                                                                                                                                                                                                                                                                                                                          | 19/07/2007          | 18/09/2007                               | SPC, Annex II, Labelling, PL     | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile continues to be favourable. The CHMP was also of the opinion that the renewal can be granted with unlimited validity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0003 | Medicinal Update of section 4.8 of the SPC and corresponding section of the Package Leaflet. Introduction of changes to reflect the CHMP Note for Guidance on Declaration of Storage Conditions and an update to bring the SPC, labelling and Package Leaflet in accordance with the latest QRD template and to harmonise with the MAH's other insulin products. | product 23/06/2004  | no longer 02/08/2004                     | SPC, Labelling, PL               | Update of section 4.8 of the SPC in order to better reflect the adverse drug reactions reported in clinical trials, to list undesirable effects using the MedDRA terminology, and to list them according to frequencies. The introduction to section 4.8 of the SPCs has also been updated to state that hypoglycaemia is the most frequent undesirable effect, but no exact frequency is included, as the frequency of hypoglycaemia is highly variable among various patient populations and dose regimens. This update of section 4.8 also includes the removal of hyperglycaemia. All information on hyperglycaemia (including symptoms) has been located in section 4.4, including the warning of the risk of fatal outcome of untreated hyperglycaemic events. The terms `diabetic retinopathy' and `painful neuropathy' have been added to section 4.8. The adverse event \"Fainting/loss of consciousness\" is also added to the list in section 4.8. These changes have been reflected in the section 5 of the Package Leaflet. |

## Velosulin

<!-- image -->

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                                                        | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |                                                                                                                                                                                              |                     |                                          |                                  | authorised In addition changes have been made to the Product Information to reflect the CHMP Note for Guidance on Declaration of Storage Conditions, linguistic amendments in accordance to the latest QRD template (version 6, 1/2004) and to harmonise with other insulin products from NovoNordisk. |
| II/0002 | Change(s) to the manufacturing process for the active substance Change(s) to the test method(s) and/or specifications for the active substance Change(s) to shelf-life or storage conditions | 25/09/2003          | 01/10/2003                               |                                  |                                                                                                                                                                                                                                                                                                        |

| No     | Scope                                                                                               | Product Information affected 2   | Date 4     |
|--------|-----------------------------------------------------------------------------------------------------|----------------------------------|------------|
| N/0007 | no Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | Labelling, PL                    | 17/03/2008 |
| N/0005 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)    |                                  | 27/04/2005 |
| I/0001 | Change in pack size for a medicinal product                                                         | SPC, Labelling, PL               | 09/07/2003 |

<!-- image -->